Initial Treatment Approach for Mixed Hyperlipidemia

Lifestyle Modifications

The American Heart Association recommends limiting saturated fat to <7% of total calories, reducing dietary cholesterol to <200 mg/day, avoiding trans-fatty acids completely, and considering adding plant stanols/sterols and increased viscous fiber to help lower cholesterol levels 1
Regular physical activity, such as at least 30 minutes of moderate-intensity physical activity on most days, and resistance training 2 days/week, can help improve lipid profiles and overall health 1
Smoking cessation is crucial for reducing cardiovascular risk, as recommended by the American Diabetes Association 2

High-potency statins, such as atorvastatin, rosuvastatin, or pitavastatin, are recommended as first-line medication for mixed hyperlipidemia, as suggested by the American College of Cardiology 1
The treatment goals for LDL-C are <100 mg/dL in the absence of ASCVD or other major risk factors, <70 mg/dL with imaging evidence of ASCVD or other major risk factors, and <55 mg/dL with clinical ASCVD, as recommended by the European Society of Cardiology 3
Triglyceride goals are <150 mg/dL, as recommended by the American Heart Association 1

Lipid profiles should be obtained after 4-12 weeks of initiating therapy to assess response, and liver function tests, creatine kinase, glucose, and creatinine should be monitored before starting therapy and periodically thereafter, as recommended by the National Lipid Association 1, 3

If statin monotherapy fails to achieve target lipid levels, adding ezetimibe or fenofibrate (not gemfibrozil) can be considered, as suggested by the American College of Cardiology 1, 3
Niacin can be considered for raising HDL-C and lowering triglycerides, but caution is advised due to potential worsening of glycemic control in diabetic patients, as recommended by the European Society of Cardiology 1

For extremely high-risk patients, a combination of high-potency statin, ezetimibe, and PCSK9-targeted therapy may be considered as first-line treatment, as suggested by the American Heart Association 3